🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🩺 [Medical Update for Hepatologists] 🩺 A recent study reveals that metformin and statins substantially reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C (CHC) who have failed antiviral therapy. Metformin use in patients with diabetes and

🚨🩺 [Critical Insights for Hepatologists] 🩺🚨 New nationwide cohort study reveals that changes in metabolic dysfunction-associated steatotic liver disease (MASLD) status significantly influence the risk of hepatocellular carcinoma (HCC). Persistent MASLD increases HCC risk

🩺 [Key Findings for Hepatologists & Oncologists] 🩺 A nationwide cohort study reveals that tenofovir disoproxil fumarate (TDF) shows approximately 30% lower risks of both extrahepatic malignancies (EHM) and intrahepatic malignancies (IHM) compared to entecavir (ETV) in chronic

📢 Advancing Hepatology This study uncovers the pivotal role of macrophage-specific ATG16L1 expression in attenuating MASH progression through enhanced lipophagy. This insight could pave the way for novel therapeutic strategies in managing metabolic dysfunction-associated liver

🧬 Advancing Hepatitis B Therapeutics This study uncovers a critical role of CIITA in inhibiting HBV replication by downregulating key hepatic transcription factors via the ERK1/2 pathway. This discovery provides potential new avenues for targeted antiviral therapies in chronic

📢 New Insight for Clinicians! Discover the impact of bariatric intervention on metabolic dysfunction-associated steatohepatitis (MASH) in obese patients. This comprehensive meta-analysis highlights potential alternative treatments for those not responding to standard therapies.

🌟 CMH session in KDDW 2024! “Distinguished papers of 2023-2024 in clinical and molecular hepatology" #Hepatology #MedicalResearch #LiverStudy #Innovation #KDDW #KASL #CMH #ClinMolMed #KASL

📷 CMH session in KDDW 2024! “Distinguished papers of 2023-2024 in clinical and molecular hepatology" Most viewed article Highly cited article Notable article on clinical research Notable article on basic/translational research Catch these groundbreaking studies and stay

🌟Fantastic discussions at the Editorial Board Meeting during The Liver Meeting 2024! Thank you for making the time to join us despite your busy schedules! #LiverTwitter #MedEd #CMH #ClinMolMed #KASL #AASLDEBMlunchmeeting

In this episode, Soon Kyu Lee and colleagues identify the optimal tacrolimus level for reducing the risk of chronic kidney disease (CKD). They also examine the impact of intrapatient variability in tacrolimus levels on CKD development, emphasizing the importance of meticulous

🩺 Optimizing CSPH Management: A New Risk Model & Carvedilol Therapy 🩺 A novel risk model based on LSM and PLT enables precise identification of high-risk patients with clinically significant portal hypertension (CSPH). 📊 Carvedilol significantly reduces the risk of hepatic

🔬✨ Phase 2a Clinical Trial on HK-660S for PSC A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of HK-660S (β-lapachone) in primary sclerosing cholangitis (PSC) patients. Results demonstrated a 15.2% reduction in ALP levels, potential

📢 USP29 stabilizes ACSL5 to mitigate MASLD Our latest study reveals that USP29 protects against MASLD progression by stabilizing ACSL5 through K48-linked deubiquitination. Enhancing the USP29-ACSL5 pathway could be a novel therapeutic strategy for MASLD management. 🔗 Read

📢 Universal HCV Self-Testing: A new approach to eliminate HCV! 🩸💡 Our latest study shows that universal HCV self-testing is highly cost-effective and can reduce severe liver disease by 71% while preventing 69% of liver-related deaths. A major step toward the WHO 2030

📌 Sex-Specific Gut Microbiota Profiles in MASLD: A Clinical Insight 🔍 Could sex differences in gut microbiota explain MASLD heterogeneity? This Clin Mol Hepatol study shows distinct microbial signatures in the jejunum and colon between males and females with MASLD. 🧠 Key

In this multicenter, retrospective study including CHC patients who were treated with DAAs and achieved a SVR, metabolic dysfunction has an unfavorable influence on fibrosis regression.

🧪 Aberrant fragmentomic features of ccf-mtDNA for early detection and prognosis prediction of HCC This is the first study to explore the clinical application of ccf-mtDNA fragmentomic features in predicting HCC prognosis, highlighting its potential as a blood-based biomarker

A rollover study from the TORCH-B trial: 3-year TDF therapy resulted in favorable histopathological, biochemical, and virological outcomes in CHB patients with minimally raised ALT. 📘 Full article: doi.org/10.3350/cmh.20… #ClinicalLiver #ChronicHepatitisB #CHB #HBV #LiverHealth

Bariatric surgery improves survival in MASLD and cirrhosis—especially with laparoscopic approach Bariatric Surgery reduced overall mortality by 37% and liver-related mortality by 76% in patients with MASLD and cirrhosis. Especially Laparoscopic surgery showed greater benefit

TIPS does more than lower portal pressure-it rewires inflammation In decompensated cirrhosis, TIPS leads to a sustained and significant drop in systemic inflammation and bacterial translocation markers (↓25 SIMs, ↓sCD14, ↓CRP), translating into improved outcomes for patients.